Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.8 EUR | 0.00% | -3.81% | -10.32% |
May. 07 | Biotest Aktiengesellschaft Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 19 | Biotest Launches New Plasma Collection Center in Germany | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- One of the major weak points of the company is its financial situation.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.32% | 1.48B | B- | ||
-3.35% | 88.91B | A- | ||
+2.76% | 41.25B | A- | ||
-14.36% | 31.99B | B- | ||
+50.51% | 24.73B | A | ||
-15.04% | 15.54B | C | ||
-39.93% | 12.07B | B | ||
-9.08% | 12.05B | D+ | ||
-15.19% | 12.02B | B- | ||
+6.22% | 8.84B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIO3 Stock
- Ratings Biotest AG